<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935089</url>
  </required_header>
  <id_info>
    <org_study_id>Merck-0575</org_study_id>
    <nct_id>NCT01935089</nct_id>
  </id_info>
  <brief_title>Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV</brief_title>
  <official_title>Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Wistar Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Wistar Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to test our primary hypothesis that treatment with Peg-IFN-α-2b will result in a&#xD;
      decrease in integrated HIV DNA in peripheral blood and tissue in chronically HIV-infected&#xD;
      immune-reconstituted individuals (see section 3.1) in a prospective, interventional, 1-arm,&#xD;
      open label clinical trial. To this end, we propose to enroll 25 HIV-1-infected subjects&#xD;
      (please refer to power calculations in section 10.1 below) currently stably suppressed (&gt; 1y&#xD;
      with VL &lt; 50 copies/ml) on ART and with CD4 count &gt; 450 cells/µl.&#xD;
&#xD;
      We hypothesize that 20 weeks of treatment with Peg-IFN-alpha-2b, in the presence of HIV&#xD;
      reactivation (i.e.: ART interruption), will result in activation of intrinsic and/or&#xD;
      immune-mediated anti-HIV mechanisms resulting in a decrease in the levels of viral reservoir&#xD;
      in chronically HIV-infected, immune-reconstituted individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in copies of HIV DNA per CD4+ T cell at Week 24</measure>
    <time_frame>Week 0 and 24</time_frame>
    <description>Assessed by Alu-HIVgag polymerase chain reaction</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Interferon alpha</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alpha 2b</intervention_name>
    <description>1µg/kg/week</description>
    <arm_group_label>Interferon alpha</arm_group_label>
    <other_name>Pegintron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-65 years of age&#xD;
&#xD;
          -  Body weight between 125 and 299 lbs&#xD;
&#xD;
          -  Confirmed diagnosis of HIV-1 infection by western blot or by a documented HIV-1 viral&#xD;
             load&#xD;
&#xD;
          -  Currently receiving ART and on ART for &gt; 1 year&#xD;
&#xD;
          -  VL &lt; 50 copies/ml for ≥ 1 year, with at least 2 measurements in the previous year, 1&#xD;
             viral &quot;blip&quot; with VL&lt; 400 copies/ml allowed&#xD;
&#xD;
          -  HIV viral load of &lt;50 copies/ml at screening.&#xD;
&#xD;
          -  CD4 &gt;450 cells/µL at screening.&#xD;
&#xD;
          -  A negative ECG if &gt;45yrs men/&gt;55yrs women years of age or if below these years of age&#xD;
             but with two added risk factors for coronary artery disease [smoking, hypertension (BP&#xD;
             &gt;140/90 or on antihypertensive medications), low HDL (&lt;40 mg/dL), family history of&#xD;
             premature CHD (&lt;55 yrs males/&lt;65 females)] or a Framingham score &gt; 15% (men) or 10%&#xD;
             (women))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed clinical history of developing resistance to ART regimens that resulted in&#xD;
             treatment changes&#xD;
&#xD;
          -  Receiving didanosine as part of the participant's ART regimen at the time of screening&#xD;
&#xD;
          -  Ongoing treatment with Isoniazide, pyrazinamide, Rifabutin, Rifampicin, Diadenosine&#xD;
             Ganciclovir, Valgancyclovir, Oxymetholone, Thalidomide or Theophylline.&#xD;
&#xD;
          -  Use of any investigational drug within 30 days prior to screening&#xD;
&#xD;
          -  History or current use of immunomodulatory therapy for over 2 weeks during the 6&#xD;
             months prior to enrollment, including, but not limited to: IFN-alpha or gamma&#xD;
             (recombinant or pegylated), systemic corticosteroids (nasal or pulmonary steroids will&#xD;
             be allowed; systemic cancer chemotherapy/irradiation; cyclosporin; tacrolimus&#xD;
             (FK-506); OKT-3; any Interleukin, including IL-2; cyclophosphamide; methotrexate; IVIG&#xD;
             (gamma globulin); G/M-CSF; hydroxyurea; thalidomide; pentoxifylline; thymopentin;&#xD;
             thymosin; dithiocarbonate; polyribonucleotide.&#xD;
&#xD;
          -  History of adverse or allergic reactions to any type-1 interferon (e.g. IFN-alpha2a,&#xD;
             IFN-α2b, IFN-beta)&#xD;
&#xD;
          -  History of severe depression, or ongoing moderate depression determined by PHQ-9 at&#xD;
             screening&#xD;
&#xD;
          -  Type I diabetes mellitus, or type II diabetes mellitus that is not controlled with&#xD;
             oral agents and/or insulin.&#xD;
&#xD;
          -  Prior diagnosis of multiple sclerosis or other neurodegenerative disorders&#xD;
&#xD;
          -  Significant co-existing lab abnormalities including:&#xD;
&#xD;
               1. Anemia (Hgb &lt;9.1 mg/dl men, &lt;8.9 mg/dl women)&#xD;
&#xD;
               2. WBC &lt;2000 cells/µl&#xD;
&#xD;
               3. Absolute neutrophil count (ANC) &lt;1200 cells/ µl&#xD;
&#xD;
               4. Platelet count &lt;60,000 cells/ µl&#xD;
&#xD;
               5. Liver disease (AST/ALT &gt; 2.5x, Total Bilirubin &gt; 1.5x upper limits of norm (ULN),&#xD;
                  or Total Bilirubin &gt;3x ULN if receiving indinavir OR Atazanavir)&#xD;
&#xD;
               6. Renal disease (creatinine &gt; 2x upper normal limits or creatinine clearance&#xD;
                  &lt;60mg/dl (by Crockoff-Gault)&#xD;
&#xD;
          -  Chronic HCV infection (HCV viremia), or HBV Ag positive and/ or HBV viremia (Notice:&#xD;
             subjects with prior HCV infection with a documented sustained virologic response with&#xD;
             treatment finishing &gt;1 year prior to screening are eligible for enrollment).&#xD;
&#xD;
          -  Liver cirrhosis or hepatic decompensation with Child Pugh score &gt; 6&#xD;
&#xD;
          -  History of major organ transplantation with an existing functional graft.&#xD;
&#xD;
          -  Evidence of OI or other active infectious diseases or active malignancies&#xD;
&#xD;
          -  Active Autoimmune diseases, including autoimmune hepatitis&#xD;
&#xD;
          -  History of retinopathy or clinically significant ophthalmologic disease on eye exam&#xD;
             performed within 6 months prior to initiation of IFN&#xD;
&#xD;
          -  Pregnancy, actively attempting to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Body weight under 125 lbs or over 300 lbs&#xD;
&#xD;
          -  Other conditions, such as active drug/alcohol abuse or dependence which would&#xD;
             interfere with study compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis J Montaner, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS Clinical Trials Unit (ACTU), and Department of Medicine, University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital, Department of Medicine, University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonathan Lax Clinic, Philadelphia FIGHT</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>August 27, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Wistar Institute</investigator_affiliation>
    <investigator_full_name>Luis Montaner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Interferon alpha</keyword>
  <keyword>Integrated DNA</keyword>
  <keyword>Latent reservoir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

